# Human Rating Form — GDgpt Clinical Utility Evaluation

> **Instructions**: Rate each question on D1-D5 (1=Poor, 3=Adequate, 5=Excellent).
> Fill in the table below. Use same rubric as the LLM judge.
> Return this file after completion.

## Rubric Summary
- **D1 Factual Accuracy**: Are gene/pathway/drug claims correct?
- **D2 Completeness**: Are key evidence items covered?
- **D3 Traceability**: Are claims attributed to specific sources/edges?
- **D4 Clinical Safety**: Does it acknowledge uncertainty vs. fabricate?
- **D5 Coherence**: Is it logically structured and readable?

---
## Question 1: `ind_dc_87845f398756`
**Q**: What genes and pathways are associated with breast neoplasm? What are the key mechanisms?

### System A (GDgpt)
```
** Breast neoplasm is associated with dysregulation of key pathways and genes, as confirmed by the knowledge graph. The **Estrogen-dependent gene expression pathway** is INVOLVED_IN tumor cell proliferation and survival, with genes such as **ESR1**, **BCL2**, **PGR**, **CCND1**, and **JUN** playing central roles; this pathway is targeted by drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors. The **PIP3 activates AKT signaling pathway**, INVOLVED_IN cell survival and proliferation, is regulated by genes **AKT1**, **ERBB2**, **KIT**, **FGF4**, and **ESR1**, and targeted by PI3K inhibitors (e.g., alpelisib) and AKT inhibitors. The **RAF/MAP kinase cascade pathway**, INVOLVED_IN oncogenic transformation, is driven by genes **KIT**, **ERBB2**, and **FGFR2**, with
```

### System B (GPT-4o)
```
Breast neoplasms are associated with several key genes and pathways that drive tumorigenesis, progression, and therapeutic resistance. Below is a concise outline of the most relevant genes, pathways, and mechanisms:

### **Genes Frequently Associated with Breast Neoplasm:**
1. **Tumor Suppressor Genes:**
   - **TP53**: Regulates cell cycle arrest, apoptosis, and DNA repair. Mutations are common in triple-negative breast cancer (TNBC).
   - **BRCA1/BRCA2**: Critical for homologous recombination (HR) DNA repair. Germline mutations increase the risk for hereditary breast and ovarian cancer syndromes.
   - **PTEN**: Regulates PI3K/AKT signaling and cell survival. Loss of PTEN is associated with aggressive phenotypes.

2. **Oncogenes:**
   - **PIK3CA**: Activates the PI3K/AKT/mTOR pathway, prom
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 2: `ind_dc_efd557a940d1`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of the corpus uteri? What are the key mechanisms?

### System A (GDgpt)
```
**  
The knowledge graph confirms that **undifferentiated carcinoma of the corpus uteri** is ASSOCIATED_WITH the **ABCA** and **ABCB** gene families, including **ABCA3**, **ABCA4**, **ABCB1**, and **ABCB10**, with potential involvement in **ABC transporters in lipid homeostasis** and multidrug resistance mechanisms [LLM-inferred]. Additionally, the disease is ASSOCIATED_WITH multiple pathways that highlight key mechanisms of tumorigenesis. **Inflammatory signaling** is implicated through the association of **NOS2**, **PTGS2**, **HMOX1**, **MAOA**, and **MMP9** with **Interleukin-4 and Interleukin-13 signaling**, suggesting roles in chronic inflammation and tumor-promoting microenvironments. **Hormonal regulation** is emphasized by the association of **ESR1**, **BCL2**, **PGR**, **CCND1**, 
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the corpus uteri is a rare and aggressive subtype of endometrial cancer characterized by high-grade histology and loss of differentiation. Its molecular mechanisms are not fully understood, but studies have identified several key genes and pathways associated with its pathogenesis:

### **Key Genes:**
1. **SWI/SNF Complex Genes**:
   - **SMARCA4**: Loss-of-function mutations in SMARCA4 (BRG1) are implicated in undifferentiated carcinoma, leading to defects in chromatin remodeling.
   - **ARID1A**: Mutations in ARID1A, another component of the SWI/SNF chromatin remodeling complex, are frequently seen in aggressive endometrial carcinomas.

2. **TP53**:
   - Mutations in TP53 are common in undifferentiated and high-grade endometrial carcinomas, leading to loss of
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 3: `ind_dc_182a1e726ac1`
**Q**: What genes and pathways are associated with schizophrenia? What are the key mechanisms?

### System A (GDgpt)
```
Schizophrenia is ASSOCIATED_WITH multiple genes, including **A1BG**, **ABCA1**, **ABCA13**, and **ABCB1**, as confirmed by the knowledge graph. These genes are INVOLVED_IN critical pathways such as the **RAF/MAP kinase cascade**, which is ASSOCIATED_WITH schizophrenia through genes **IL3**, **PDGFRB**, **GRIN1**, **GRIN2D**, and **GRIN2B**, playing roles in neuronal cell survival, differentiation, and glutamatergic neurotransmission. Additionally, schizophrenia is ASSOCIATED_WITH **G alpha (i) signaling events** and **G alpha (q) signaling events**, mediated by genes such as **ADORA1**, **CNR1**, **CHRM1**, and others, which regulate GPCR signaling critical for neurotransmitter regulation and synaptic plasticity. Immune-related pathways, including **Neutrophil degranulation** and **Interle
```

### System B (GPT-4o)
```
Schizophrenia is a complex neuropsychiatric disorder with both genetic and environmental contributors. While no single gene is solely responsible, several genes and pathways have been implicated in its pathogenesis. Below is a concise summary of key genes, pathways, and mechanisms:

### Key Genes:
1. **COMT (Catechol-O-Methyltransferase):** Involved in dopamine metabolism; polymorphisms (e.g., Val158Met) may affect dopamine signaling in the prefrontal cortex.
2. **DISC1 (Disrupted in Schizophrenia 1):** Plays a role in neuronal development, synaptic signaling, and brain connectivity.
3. **NRG1 (Neuregulin 1):** Involved in synaptic plasticity and myelination.
4. **DRD2 (Dopamine D2 Receptor):** A key target of antipsychotic medications; altered dopamine receptor signaling is central to sch
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 4: `ind_dc_9c33ed784d74`
**Q**: What genes and pathways are associated with colorectal cancer? What are the key mechanisms?

### System A (GDgpt)
```
Colorectal cancer is ASSOCIATED_WITH several genes, including **A2M**, **ABCA1**, **ABCA10**, and **ABCA12**, per the knowledge graph. Among these, **A2M** is INVOLVED_IN the **Degradation of the extracellular matrix** pathway, which facilitates tumor invasion and metastasis, alongside **MMP9**, which also INTERACTS_WITH this pathway. The **Neutrophil degranulation** pathway, which fosters a pro-inflammatory tumor microenvironment, is INTERACTED_WITH by **ALOX5** and **MPO**. Additionally, **NOS2** and **VEGFA** are INVOLVED_IN the **Interleukin-4 and Interleukin-13 signaling** pathway, highlighting roles in immune modulation and angiogenesis. The **Ub-specific processing proteases** pathway, which underscores genomic instability and disrupted tumor suppression, is INTERACTED_WITH by **TP5
```

### System B (GPT-4o)
```
Colorectal cancer (CRC) is associated with a complex interplay of genetic alterations and dysregulated signaling pathways. Key genes and pathways involved include:

### 1. **APC/β-Catenin (Wnt Signaling Pathway):**
   - **Genes:** APC (tumor suppressor), CTNNB1 (encodes β-catenin).
   - **Mechanism:** Loss-of-function mutations in APC lead to aberrant activation of Wnt signaling, allowing β-catenin to accumulate and translocate to the nucleus, where it drives transcription of oncogenic target genes like MYC and CCND1.

### 2. **TP53 (Tumor Suppressor Pathway):**
   - **Gene:** TP53.
   - **Mechanism:** Mutations in TP53 disrupt cell cycle arrest, apoptosis, and DNA repair, promoting genomic instability and tumor progression.

### 3. **KRAS/NRAS and MAPK Pathway:**
   - **Genes:** KRAS, NRA
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 5: `ind_dc_6847df815fd5`
**Q**: What genes and pathways are associated with familial prostate carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Familial prostate carcinoma is ASSOCIATED_WITH several genes, including **AAAS**, **ABCC4**, **ABCG5**, and **ABO**, as confirmed by the knowledge graph. It is LINKED_TO key pathways such as **PI3K/AKT signaling dysregulation** (via genes **ERBB2**, **AKT1**, and **EGFR**) and the **RAF/MAP kinase cascade** (via genes **EGFR**, **MET**, and **PIK3R1**), which drive cell proliferation, survival, and oncogenesis. Immune-related pathways, including **Neutrophil degranulation** (via genes **B2M**, **ALOX5**, **MME**, **GSTP1**, **CTSB**) and **Interleukin-4/Interleukin-13 signaling** (via genes **ALOX5**, **PTGS2**, **HMOX1**, **MMP9**, **VEGFA**), suggest chronic inflammation and oxidative stress contribute to the tumor microenvironment. Additionally, **BRCA2** is LINKED_TO DNA repair pathway
```

### System B (GPT-4o)
```
Familial prostate carcinoma is associated with several genes and pathways that influence hereditary predisposition and tumorigenesis. Key genes and mechanisms include:

### **Genes and Pathways**
1. **DNA Damage Repair Pathways**
   - **BRCA1/BRCA2**: Mutations in these genes, primarily known for their role in breast and ovarian cancers, are also implicated in prostate cancer, especially aggressive forms. They impair homologous recombination repair of DNA damage, leading to genomic instability.
   - **ATM**: A gene involved in DNA damage response. Loss-of-function mutations in ATM can lead to defective repair mechanisms and increased cancer risk.
   - **CHEK2**: Encodes a checkpoint kinase involved in DNA repair. Mutations in CHEK2 are linked to familial prostate cancer due to impaired cel
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 6: `ind_dc_3bb0a1cdbe69`
**Q**: What genes and pathways are associated with hepatocellular carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Hepatocellular carcinoma (HCC) is ASSOCIATED_WITH the genes **A2M**, **AADAT**, **ABCB1**, and **ABCB4**, as confirmed by the knowledge graph, although their specific mechanistic roles remain unclear. Several pathways are implicated in HCC through gene-pathway interactions: **Neutrophil degranulation** is INTERACTED_WITH by genes such as **SERPINA1** and **GSTP1**, suggesting immune dysregulation and inflammation as contributors to HCC progression. **Resolution of Sister Chromatid Cohesion** and **Separation of Sister Chromatids** are INTERACTED_WITH by genes including **CDK1**, **AURKB**, **BIRC5**, **CENPE**, and **PLK1**, indicating genomic instability due to disrupted cell division and chromosomal segregation. **Interleukin-4 and Interleukin-13 signaling** is INTERACTED_WITH by genes s
```

### System B (GPT-4o)
```
Hepatocellular carcinoma (HCC) is associated with several genetic alterations and pathways that drive tumor development and progression. Below is a summary of key genes, pathways, and mechanisms involved:

### 1. **Key Genes Associated with HCC**
   - **TP53**: Frequently inactivated in HCC, leading to loss of cell cycle regulation and genomic instability.
   - **CTNNB1 (β-catenin)**: Activating mutations result in constitutive activation of the Wnt/β-catenin signaling pathway, promoting cell proliferation and survival.
   - **TERT (telomerase reverse transcriptase)**: Promoter mutations upregulate telomerase activity, leading to immortalization of cancer cells.
   - **AXIN1**: Mutations in this negative regulator of Wnt signaling enhance β-catenin activity.
   - **ARID1A/ARID2**: Loss-of-
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 7: `ind_dc_d130a7eb1f15`
**Q**: What genes and pathways are associated with adenocarcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Adenocarcinoma of the liver and intrahepatic biliary tract is driven by multiple mechanisms supported by the knowledge graph. The gene **A2M** is ASSOCIATED_WITH adenocarcinoma of the liver and intrahepatic biliary tract and INVOLVED_IN pathways such as **Degradation of the extracellular matrix**, which facilitates tumor invasion and metastasis, and the **Intrinsic Pathway of Fibrin Clot Formation**, suggesting vascular remodeling. Chromosomal instability is linked to genes such as **CDK1**, **AURKB**, **BIRC5**, **CENPE**, and **PLK1**, which are INVOLVED_IN pathways like **Resolution of Sister Chromatid Cohesion** and **Separation of Sister Chromatids**, contributing to mitotic errors and aneuploidy. Cytoskeletal remodeling and metastasis are facilitated by the **RHO GTPases Activate For
```

### System B (GPT-4o)
```
Adenocarcinoma of the liver and intrahepatic biliary tract (encompassing hepatocellular carcinoma [HCC] and intrahepatic cholangiocarcinoma [iCCA]) involves several genes and pathways that drive tumorigenesis. Below is a concise overview:

### 1. **Hepatocellular Carcinoma (HCC)**
   - **Key Genes**:
     - **TP53**: Frequently mutated, leading to loss of tumor suppressor function.
     - **CTNNB1 (β-catenin)**: Mutations drive Wnt/β-catenin pathway activation.
     - **TERT**: Promoter mutations result in telomerase activation and genomic stability.
     - **AXIN1**: Mutations impair Wnt pathway regulation.
     - **ARID1A/ARID2**: Chromatin remodeling gene mutations contribute to epigenetic dysregulation.
   
   - **Key Pathways**:
     - **Wnt/β-catenin pathway**: Aberrant activation pr
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 8: `ind_dc_8df2021cf75b`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
The undifferentiated carcinoma of the liver and intrahepatic biliary tract is ASSOCIATED_WITH multiple genes, including **A2M**, **AADAT**, **ABCB1**, and **ABCB4**, as confirmed by the knowledge graph. **A2M** is INTERACTS_WITH pathways such as **Degradation of the extracellular matrix**, **HDL assembly**, and **Intrinsic Pathway of Fibrin Clot Formation**, suggesting its role in tumor microenvironment remodeling and coagulation. **ABCB1** and **ABCB4**, as ABC transporters, are ASSOCIATED_WITH drug resistance and bile transport dysfunction, potentially influencing carcinogenesis. **AADAT** is ASSOCIATED_WITH amino acid metabolism, which may impact cancer cell survival. Chromosomal instability is a key driver of the disease, with pathways such as **Resolution of Sister Chromatid Cohesion*
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the liver and intrahepatic biliary tract is rare, and its molecular underpinnings are not fully characterized. However, based on available data, key genes and pathways potentially associated with this tumor type include:

### Associated Genes:
1. **TP53**: Frequently mutated in poorly differentiated or aggressive liver and biliary tract cancers, leading to impaired DNA damage response and cell cycle regulation.
2. **KRAS**: Activating mutations in KRAS are common in intrahepatic cholangiocarcinoma, driving growth and proliferation through MAPK/ERK signaling.
3. **IDH1/IDH2**: Mutations in these genes are seen in cholangiocarcinoma, resulting in abnormal 2-hydroxyglutarate production and epigenetic dysregulation.
4. **FGFR2**: Fusions in FGFR2 are specifically 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 9: `ind_dc_f30ad13c7079`
**Q**: What genes and pathways are associated with squamous cell carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Squamous cell carcinoma of the liver and intrahepatic biliary tract is ASSOCIATED_WITH the genes **A2M**, **AADAT**, **ABCB1**, and **ABCB4** per the knowledge graph. **A2M** is INVOLVED_IN pathways such as **Degradation of the extracellular matrix** and **Intrinsic Pathway of Fibrin Clot Formation**, suggesting roles in tumor invasion and metastasis. **ABCB1** and **ABCB4** are ASSOCIATED_WITH multidrug resistance and bile transport, respectively, potentially contributing to chemotherapy resistance and bile-related pathophysiology [LLM-inferred]. **AADAT** is ASSOCIATED_WITH the disease, but its precise role remains unclear. Pathways such as **Resolution of Sister Chromatid Cohesion**, **Separation of Sister Chromatids**, and **Amplification of signal from unattached kinetochores via a MA
```

### System B (GPT-4o)
```
Squamous cell carcinoma (SCC) of the liver and intrahepatic biliary tract is an extremely rare malignancy, and its molecular mechanisms are not well characterized. However, based on existing knowledge from biliary tract cancers and SCCs in other sites, several genes and pathways may be implicated:

### Key Genes and Pathways:
1. **TP53**: Mutations in TP53 are frequently observed in biliary tract cancers and SCCs, leading to loss of cell cycle regulation and genomic instability.

2. **KRAS**: Mutations in KRAS are common in biliary tract cancers and may play a role in SCC transformation by activating the MAPK/ERK signaling pathway.

3. **PIK3CA/AKT/mTOR Pathway**: Dysregulation of this pathway, through PIK3CA mutations or PTEN loss, is implicated in various SCCs and biliary tract malignanc
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |
